Extracellular Matrix Coated Stent for Controlled Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug-eluting stents face challenges with physical, chemical, and therapeutic legacy in the vessel, as well as issues related to thickness, deployment flexibility, access to difficult lesions, and minimization of vessel wall intrusion.
Innovation Solution
A stent with a coating comprising a polymer and an active agent, where the active agent includes extracellular matrix components such as heparin sulfate, chondroitin sulfate, and collagen, applied in multiple layers to ensure optimal coverage and release, with a bioabsorbable polymer like PLGA for controlled delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a coating is applied to the stent to address restenosis and promote healing, then therapeutic efficacy is improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The coating is divided into multiple discrete layers including a polymer layer and an active agent layer, allowing each layer to be optimized independently for its specific function while simplifying the overall manufacturing process
Solution Approach 2:
The coating combines a polymer matrix with embedded active agents (extracellular matrix components) to create a composite structure that provides both structural integrity and therapeutic functionality in a single integrated coating system
2Reliability
If the coating thickness is increased to improve drug delivery, then therapeutic effect is enhanced, but deployment flexibility and access to difficult lesions are reduced
Solution Approach 1:
The active agents are distributed throughout the coating structure with varying concentrations in different layers, allowing optimized drug release profiles without requiring uniform increases in overall coating thickness
Solution Approach 2:
The polymer coating is designed with a porous structure that enables controlled drug release through diffusion, providing effective therapeutic delivery through a thin coating that maintains stent flexibility and deployability
3Stability of the object's composition
If a durable polymer is used for the coating, then coating stability is improved, but long-term vascular impact and therapeutic legacy are increased
Solution Approach 1:
The polymer coating is designed to change its properties over time, transitioning from a stable structure that maintains coating integrity to a degradable state that allows complete resorption, eliminating long-term vascular foreign body presence
Solution Approach 2:
The bioabsorbable polymer is designed to degrade and be completely resorbed by the body after delivering its therapeutic function, with the degradation products being metabolized and eliminated, leaving no permanent foreign material in the vasculature
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a stent with improved biocompatibility and controlled release of active agents, reducing vascular intrusion and enhancing deployment flexibility while minimizing long-term vascular impact.
Implementation Method 1
controlled release of active agents
Implementation Method 2
bioabsorbable polymer like PLGA for controlled delivery
Implementation Method 3
improved biocompatibility
Data Source
AI summary
Provided herein are devices comprising a stent; and a coating on said stent comprising a polymer and an active agent, wherein the active agent comprises at least one of: extracellular matrix and an extracellular matrix component. Provided herein are methods of preparing a device comprising a stent and a coating on said stent; said method comprising: providing a stent; and forming a plurality of layers on said stent; wherein the coating comprises a polymer and at least one of said layers comprises one or more active agents; wherein at least a portion of the active agent comprises at least one of extracellular matrix and an extracellular matrix component.